A doctor mentions gabapentin for your anxiety, or you read about it on a forum and wonder why nobody has offered it. Neurontin has no FDA approval for any anxiety disorder, and its evidence is uneven: reasonably good for one narrow setting, mixed for others. Here is what that looks like when laid out condition by condition.
What we know and what we do not
| Well established | Still uncertain |
|---|---|
| Neurontin’s labeled uses are nerve pain after shingles and add-on treatment of partial onset seizures | How well it works for everyday generalized anxiety or panic |
| Off-label prescribing is legal and common | Whether benefit lasts over the long term in anxiety disorders |
| Gabapentin reduces anxiety before surgery in pooled trials | Whether that surgical result applies to ongoing anxiety disorders |
| It can cause sedation, dizziness and, with some drugs and conditions, breathing problems | The best dose or duration for anxiety |
| Stopping suddenly can cause withdrawal symptoms, including anxiety | How much misuse risk adds to the decision for a given person |
The official position is straightforward. The Neurontin label lists management of postherpetic neuralgia in adults and adjunctive therapy for partial onset seizures. Anxiety appears only as a reported withdrawal symptom, not as a use. FDA says that once a drug is approved, providers generally may prescribe it for an unapproved use if they judge it medically appropriate, and it notes that it has not determined the drug safe and effective for that use.
What the research actually shows
Two reviews are worth reading together. They differ in time and approach but point the same way.
A 2022 systematic review and meta-analysis in Molecular Psychiatry examined gabapentin and pregabalin in bipolar disorder, anxiety and insomnia, identifying 55 double-blind randomized trials and 15 open-label studies. Across the anxiety spectrum, it found “a consistent but not universal effect” favoring the gabapentinoids over placebo, and it concluded there is “moderate evidence of the efficacy of gabapentinoids in anxiety states.” It added that these drugs should be used for such disorders “only with strong justification.” Keep in mind that this group of drugs includes pregabalin, and the pooled conclusion cannot simply be assigned to gabapentin alone.
A 2019 systematic review in Frontiers in Psychiatry looked only at gabapentin and said it “appears to be effective in some forms of anxiety disorders,” naming preoperative anxiety, anxiety in breast cancer survivors and social phobia. It described gabapentin as more effective as an adjunct than as monotherapy. It also noted that it “has yet to be determined whether GBP is effective in treating severe and recurring anxiety,” and that many of the studies reviewed were open-label.
| Setting | Evidence we found for gabapentin | How to read it |
|---|---|---|
| Anxiety before surgery | Better than placebo in the 2022 pooled analysis (standardized mean difference -0.92) | The clearest signal, in a short, one-time setting, among people who mostly did not have an anxiety disorder |
| Social phobia | A 14-week placebo-controlled study of 69 patients found a significant reduction in symptoms | A single modest trial from 1999; the authors called the data limited and asked for further studies |
| Panic disorder | An 8-week trial of 103 patients found no overall difference from placebo | A post hoc analysis suggested possible benefit in more severely ill patients, which is hypothesis-generating only |
| Generalized anxiety and severe recurring anxiety | No firm conclusion in the reviews we read | Ask what the rationale is for your case |
Why a clinician might still suggest it
MedlinePlus says the main treatments for anxiety disorders are psychotherapy, medicines or both, and it names cognitive behavioral therapy among therapy options and anti-anxiety drugs and select antidepressants among medicines. Gabapentin may enter the discussion when someone has not responded to these, when side effects were a problem, or when another condition such as nerve pain or sleep disturbance is also being addressed. Those reasons can be legitimate, and a good prescriber should be able to explain which applies to you. Our page on anxiety disorders and treatment pathways sets out the usual sequence.
The risks that come with any use
Off-label does not change the safety profile. A few label points deserve attention for someone considering this medicine for anxiety.
Sedation and dizziness. In the label, somnolence occurred in 19% of patients on Neurontin versus 9% on placebo in epilepsy trials, and dizziness in 17% versus 7%. The label says patients should not drive until they have gained sufficient experience to assess impairment.
Suicidal thoughts. The label warns that antiepileptic drugs, including Neurontin, increase the risk of suicidal thoughts or behavior. MedlinePlus reports that about 1 in 500 people in clinical studies of these drugs developed such thoughts, sometimes within a week of starting. It lists panic attacks, agitation and new or worsening anxiety as signs to report right away.
Breathing problems. On December 19, 2019, FDA warned of serious breathing problems with gabapentinoids in people with respiratory risk factors: use of opioids or other central nervous system depressants such as benzodiazepines, conditions like COPD, and older age.
Misuse and withdrawal. The label says gabapentin is not a controlled substance federally, but it reports misuse and abuse in the postmarketing setting. It also reports withdrawal symptoms, and says the dose should be tapered over at least one week when stopping.
That last pair is especially relevant here. Anxiety and insomnia appear on the label as reported withdrawal reactions. If someone stops abruptly and their anxiety spikes, it can be mistaken for proof that they “need” the medicine. Our guide on stopping gabapentin covers this.
Benzodiazepines are often prescribed for anxiety, and combining them with gabapentin is exactly the sort of combination FDA singled out. Our separate article on gabapentin, opioids and breathing risk explains what to watch for. Alcohol belongs on that list too, since FDA advises telling your clinician about all substances you use.
Thoughts of harming yourself: call or text 988, or call 911 if you are in immediate danger. Confusion, extreme sleepiness, unusual dizziness, slowed or shallow breathing, unresponsiveness, or bluish lips or skin: FDA says these need medical attention right away, as they can be life-threatening.
A decision checklist to bring with you
- Which anxiety diagnosis are we treating, and has it been properly assessed?
- Have I had an adequate trial of therapy, or of a first-line medicine? If not, why start here?
- Is this meant to be short-term or ongoing? What is the plan and timeline for stopping?
- Do I take anything that increases breathing or sedation risk, including opioids, benzodiazepines, alcohol or sleep aids? Do I have COPD or sleep apnea?
- Do I have a history of substance use that should change this decision?
- What improvement would justify continuing, and when will we reassess?
For a question like this, a clinician saying “the evidence is mixed, and here is why I think it is still reasonable for you” is a good sign. An answer that treats the drug as a simple anxiety pill should prompt a follow-up question. If you are already taking it and doing well, this is no reason to stop on your own; if you want to review whether it is still the right choice, ask for a planned conversation about it.
Three situations, three different conversations
Someone with long-standing generalized anxiety who has never had therapy. MedlinePlus lists psychotherapy and medication as main treatments. Asking about therapy first, or alongside medication, is a sensible step. If gabapentin is proposed before anything else has been tried, ask what makes it a better starting point for you.
A person with nerve pain and anxiety. A clinician may be choosing gabapentin chiefly for a labeled or better-supported pain use, with anxiety as a possible secondary benefit. That can be reasonable, as long as you know what the primary goal is and how it will be judged.
A person who uses opioids, benzodiazepines or alcohol regularly. This is the group FDA’s breathing warning speaks to most directly. The risk does not rule the drug out in every case, but it does mean a careful review of all substances, starting doses and monitoring. Someone with a history of substance misuse should raise this directly, since the label reports misuse and abuse in the postmarketing setting.
A note on state rules
The Neurontin label says gabapentin is not a federally controlled substance. State rules can differ and can change. A pharmacist can tell you what applies where you live, and it can affect refills and travel with your medicine. Our article on whether gabapentin is a controlled substance explains the background.
Sources
- DailyMed: Neurontin (gabapentin) prescribing information
- Hong et al., Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia, Mol Psychiatry 2022
- Ahmed et al., Use of gabapentin in substance use and psychiatric disorders, Front Psychiatry 2019
- Pande et al., Treatment of social phobia with gabapentin, J Clin Psychopharmacol 1999
- Pande et al., Placebo-controlled study of gabapentin treatment of panic disorder, J Clin Psychopharmacol 2000
- FDA Drug Safety Communication on gabapentinoids, December 19, 2019
- FDA: Understanding unapproved use of approved drugs
- MedlinePlus: Gabapentin
- MedlinePlus: Anxiety
Evidence checked November 9, 2026. General information only; do not start or stop this medicine without talking to your prescriber.